GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Skystar Bio-Pharmaceutical Co (GREY:SKBI) » Definitions » ROE %

Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) ROE % : 16.64% (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is Skystar Bio-Pharmaceutical Co ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Skystar Bio-Pharmaceutical Co's annualized net income for the quarter that ended in Sep. 2014 was $19.64 Mil. Skystar Bio-Pharmaceutical Co's average Total Stockholders Equity over the quarter that ended in Sep. 2014 was $118.00 Mil. Therefore, Skystar Bio-Pharmaceutical Co's annualized ROE % for the quarter that ended in Sep. 2014 was 16.64%.

The historical rank and industry rank for Skystar Bio-Pharmaceutical Co's ROE % or its related term are showing as below:

SKBI's ROE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 4.14
* Ranked among companies with meaningful ROE % only.

Skystar Bio-Pharmaceutical Co ROE % Historical Data

The historical data trend for Skystar Bio-Pharmaceutical Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skystar Bio-Pharmaceutical Co ROE % Chart

Skystar Bio-Pharmaceutical Co Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.99 22.47 17.12 6.74 10.19

Skystar Bio-Pharmaceutical Co Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.24 8.58 3.53 10.04 16.64

Competitive Comparison of Skystar Bio-Pharmaceutical Co's ROE %

For the Drug Manufacturers - General subindustry, Skystar Bio-Pharmaceutical Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Skystar Bio-Pharmaceutical Co's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Skystar Bio-Pharmaceutical Co's ROE % distribution charts can be found below:

* The bar in red indicates where Skystar Bio-Pharmaceutical Co's ROE % falls into.



Skystar Bio-Pharmaceutical Co ROE % Calculation

Skystar Bio-Pharmaceutical Co's annualized ROE % for the fiscal year that ended in Dec. 2013 is calculated as

ROE %=Net Income (A: Dec. 2013 )/( (Total Stockholders Equity (A: Dec. 2012 )+Total Stockholders Equity (A: Dec. 2013 ))/ count )
=10.53/( (96.215+110.393)/ 2 )
=10.53/103.304
=10.19 %

Skystar Bio-Pharmaceutical Co's annualized ROE % for the quarter that ended in Sep. 2014 is calculated as

ROE %=Net Income (Q: Sep. 2014 )/( (Total Stockholders Equity (Q: Jun. 2014 )+Total Stockholders Equity (Q: Sep. 2014 ))/ count )
=19.636/( (113.502+122.505)/ 2 )
=19.636/118.0035
=16.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2014) net income data. ROE % is displayed in the 30-year financial page.


Skystar Bio-Pharmaceutical Co  (GREY:SKBI) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2014 )
=Net Income/Total Stockholders Equity
=19.636/118.0035
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(19.636 / 73.412)*(73.412 / 164.0865)*(164.0865 / 118.0035)
=Net Margin %*Asset Turnover*Equity Multiplier
=26.75 %*0.4474*1.3905
=ROA %*Equity Multiplier
=11.97 %*1.3905
=16.64 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2014 )
=Net Income/Total Stockholders Equity
=19.636/118.0035
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (19.636 / 22.488) * (22.488 / 21.6) * (21.6 / 73.412) * (73.412 / 164.0865) * (164.0865 / 118.0035)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8732 * 1.0411 * 29.42 % * 0.4474 * 1.3905
=16.64 %

Note: The net income data used here is four times the quarterly (Sep. 2014) net income data. The Revenue data used here is four times the quarterly (Sep. 2014) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Skystar Bio-Pharmaceutical Co ROE % Related Terms

Thank you for viewing the detailed overview of Skystar Bio-Pharmaceutical Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Business Description

Traded in Other Exchanges
N/A
Address
No. 48 Keji Road, 4/F Building B, Chuangye Square, Gaoxin District, Xian, Shaanxi Province, CHN
Skystar Bio-Pharmaceutical Co is a holding company. Through its subsidiaries, it is engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products in the People's Republic of China. The company provides individually packaged animal wellness and pharmaceutical products for retail sale. It generates revenue from the sales of four product lines namely, veterinary medications, micro-organism, feed additives, and vaccines. The firm develops, manufactures, packages and distributes vaccines; Western medicines, Traditional Chinese Medicine; topicals, supplements, probiotics; diagnostic kits and animal nutrition supplements for poultry, livestock, marine aquaculture and domesticated pets.

Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Headlines

No Headlines